Cyclerion Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDCyclerion Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings contraction of 219% provides fundamental context to the price action. However, price is extended 34% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.08 | +5.08% | ABOVE |
| 50 SMA | $2.42 | +33.62% | ABOVE |
| 100 SMA | $1.92 | +69.12% | ABOVE |
| 150 SMA | $1.91 | +70.05% | ABOVE |
| 200 SMA | $2.07 | +56.72% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CYCN in an uptrend right now?
CYCN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CYCN overbought or oversold?
CYCN's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is CYCN outperforming the market?
CYCN has a Relative Strength (RS) Rating of 96 out of 99. Yes, CYCN is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is CYCN in its 52-week range?
CYCN is trading at $3.24, which is 38% of its 52-week high ($8.48) and 30% above its 52-week low ($1.03).
How volatile is CYCN?
CYCN has a Beta of 0.94 and 52-week volatility of 105%. It's less volatile than the S&P 500 - generally more stable.